1. Kroken RA., Loberg EM., et al. A critical review of pro-cognitive drug targets in psychosis: convergence on myelination and inflammation. 2014. Frontiers in Psychiatry, 5(11), 1-13. doi:10.3389/fpsyt.2014.00011
2. Smyth AM., Lawrie SM. . The neuroimmunology of schizophrenia. 2013. Clinical Psychopharmacology and Neuroscience, 11(3), 107-117. doi:10.9758/cpn.2013.11.3.107
3. Karanikas, EP. Psycho-immunological Mechanisms in Schizophrenia. 2011. Psychiatriki, 43-52
4. Berk M., Dean O., et al. Aspirin: a review if its neurobiological properties and therapeutic potential for mental illness. 2013. BMC Medicine, 11(74), 1-17. doi:https://doi.org/10.1186/1741-7015-11-74
5. Potvin S., Stip E., et al. Inflammatory Cytokine Alterations in Schizophrenia: A Systematic Quantitative Review. 2008. Biol Psychiatry, 63(8), 801-808. doi:10.1016/j.biopsych.2007.09.024
6. Kirkpatrick B., Miller BJ. Inflammation and Schizophrenia. 2013. Schizophrenia Bulletin, 39(6), 1174-1179. doi:10.1093/schbul/sbt141
7. Miller BJ., Buckley P., et al. Meta-Analysis of Cytokine Alterations in Schizophrenia: Clinical Status and Antipsychotic Effects. 2011. HHS Public Access, 70(7), 663-671. doi: 10.1016/j.biopsych.2011.04.013
8. Girgis R., Kumar S., et al. The cytokine model of schizophrenia: emerging therapeutic strategies. 2014. Biology Psychiatry, 75(4), 292-299. doi:10.1016/j.biopsych.2013.12.002
9. Benros M., et al. The epidemiologic evidence linking autoimmune diseases and psychosis. 2014. Biology Psychiatry, 75(4), 300-306. doi:10.1016/j.biopsych.2013.09.023
10. Berckel BN., Bossong MG., et al. Microglia Activation in Recent-Onset Schizophrenia: A Quantitative (R)-[11C]PK11195 Positron Emission Tomography Study. 2008. Biol Psychiatry, 64(9), 820-822. doi:10.1016/j.biopsych.2008.04.025
11. Doorduin J., Vries EF., et al. Neuroinflammation in Schizophrenia-Related Psychosis: A PET Study. 2009. J Nucl Med, 50(11), 1801-1807. doi:10.2967/jnumed.109.066647
12. Nitta M., Kishimoto T., et al. Adjunctive use of nonsteroidal anti-inflammatory drugs for schizophrenia: a meta-analytic investigation of randomized controlled trials. 2013. Schizophrenia Bulletin, 39(6), 1230-1241. doi:10.1093/schbul/sbt070
13. Laan W., Selten JP., et al. Acetylsalicylic acid as an adjuvant therapy for schizophrenia. 2006. Trials, 7(31), 31. doi:10.1186/1745-6215-7-31
14. Laan W., Grobbee DE., et al. Adjuvant Aspirin Therapy Reduces Symptoms of Schizophrenia Spectrum Disorders: Results From a Randomized, Double-Blind, Placebo-Controlled Trial. 2010. The Journal of Clinical Psychiatry, 71(5), 520-527. doi:https://doi.org/10.4088/JCP.09m05117yel
15. Webb JR., Dorothy E., et al. Aspirin as an Adjunctive Treatment For Childhood Onset Schizophrenia. 2013. Journal of Child and Adolescent Psychopharmacology, 23(8), 585-586. doi:10.1089/cap.2013.0033
16. Cakici N., Beveren NJ., et al. An Update on the Efficacy of Anti-Inflammatory Agents for Patients With Schizophrenia: A Meta-Analysis. 2019. Psychol Med, 49(14), 2307-2319. doi:10.1017/S0033291719001995
17. Schmidt L., Phelps E., et al. Acetylsalicylic acid (aspirin) for schizophrenia. Cochrane Database of Systematic Reviews. 2019, Issue 8. Art. No.: CD012116. DOI: 10.1002/14651858.CD012116.pub2
18. Weiser M, Zamora D, et al. Adjunctive Aspirin vs Placebo in Patients With Schizophrenia: Results of Two Randomized Controlled Trials. 2021. Schizophr Bull. 47(4):1077-1087. doi: 10.1093/schbul/sbaa198. PMID: 33479775; PMCID: PMC8266648.
19. Shader RI. Too Good to Be True? Aspirin and Schizophrenia. 2012. Journal of Clinical Psychopharmacology, 32(5), 5-6. doi:10.1097/JCP.0b013e31826c448b